RESUMO
MXenes have received much attention as promising candidates for noble metal-free hydrogen evolution reaction (HER) electrocatalysts due to their high electrical conductivity, surface hydrophilicity, abundant surface functional groups, and great potential for rational hybridization with other materials. Herein, a novel porous monolayered-Ti3C2Tx@NiCoP (P-Ti3C2Tx@NiCoP) nanostructure was synthesized with uniform distribution of bimetallic compounds for improved charge transfer capability and electrocatalytic activity. In experiments, H2O2-utilized oxidation formed a highly mesoporous structure with a maximized surface area of monolayered MXenes as the support. A subsequent solvothermal process followed by phosphidation enabled successful anchoring of highly HER-active NiCoP nanoclusters onto abundantly exposed terminal edges of the P-Ti3C2Tx support. The structural porosity of the P-Ti3C2Tx nanoflakes played an important role in creating additional room for embedding catalytically active species while stably imparting high electrical conductivity to accelerate charge transfer to NiCoP nanoclusters. With structural modification and effective hybridization, P-Ti3C2Tx@NiCoP showed highly enhanced HER activity with significantly lower overpotentials of 115 and 101 mV at a current density of -10 mA cm-2 in 0.5 M H2SO4 and 1.0 M KOH, respectively, along with showing long-term stability over 60 h. As such, our approach of designing structurally modified-Ti3C2Tx and hybridizing with other electrocatalytically active species would function as a solid platform for implementing Ti3C2Tx-based hetero-nanostructures to achieve state-of-the-art performance in next-generation energy conversion applications.
RESUMO
Background: Diabetes mellitus (DM) is a well-known risk factor for adverse cardiovascular events in patients receiving percutaneous coronary intervention (PCI). Limited data are available on the relative performance of different types of contemporary drug-eluting stents (DES) for diabetic patients. Objectives: The authors investigated the effectiveness and safety profiles of several contemporary DES in patients with DM in a "real-world" clinical setting. Methods: Among 24,516 patients enrolled in a multicenter, prospective registry, 7,823 patients with DM were treated with 4 contemporary DES: 2,877 with a cobalt chromium everolimus-eluting stent (EES), 789 with a biodegradable polymer biolimus-eluting stent, 2,286 with a platinum chromium-EES, and 1,871 with a Resolute zotarolimus-eluting stent. The primary outcome was target vessel failure (TVF) (a composite of cardiac death, target vessel myocardial infarction, and target vessel revascularization). Results: The median follow-up duration was 2.9 years. Observed 3-year rates of TVF were not significantly different according to different DES types. On multigroup propensity-score analysis, the adjusted HRs for TVF were similar in between-group comparisons: biodegradable polymer biolimus-eluting stent (HR: 0.94; 95% CI: 0.76-1.16; P = 0.57), platinum chromium-EES (HR: 0.94; 95% CI: 0.81-1.09; P = 0.41), and Resolute zotarolimus-eluting stent (HR: 1.01; 95% CI: 0.86-1.18; P = 0.93) compared with the cobalt chromium-EES (reference). This trend was maintained in patients with non-insulin- and insulin-treated DM. Conclusions: In this multicenter clinical-practice PCI registry, no significant between-group differences were found for a 3-year risk of TVF in patients with DM undergoing PCI with various types of contemporary DES. (Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice [IRIS-DES]; NCT01186133).
RESUMO
BACKGROUND: Sarcopenia contributes to increased morbidity and mortality in patients undergoing surgery for abdominal aortic aneurysms (AAA). However, few reports have demonstrated whether sarcopenia would affect the development of postoperative acute kidney injury (AKI) in these patients. This study aimed to examine whether sarcopenia is associated with AKI and morbidity and mortality after infrarenal AAA operation. METHODS: We retrospectively analysed 379 patients who underwent infrarenal AAA surgery. The diagnosis of sarcopenia was performed using the skeletal muscle index, which was calculated from axial computed tomography at the level of L3. The patients were separated into those with sarcopenia (n = 104) and those without sarcopenia (n = 275). We applied multivariable and Cox regression analyses to evaluate the risk factors for AKI and overall mortality. A propensity score matching (PSM) evaluation was done to assess the postoperative results. RESULTS: The incidence of AKI was greater in sarcopenia than non-sarcopenia group before (34.6% vs. 15.3%; p < 0.001) and after the PSM analysis (34.6% vs. 15.4%; p = 0.002). Multivariable analysis revealed sarcopenia to be associated with AKI before (p = 0.010) and after PSM (p = 0.016). Sarcopenia was also associated with overall mortality before (p = 0.048) and after PSM (p = 0.032). A Kaplan-Meier analysis revealed that overall mortality was elevated patients with sarcopenia before and after PSM than in those without (log-rank test, p < 0.001, p = 0.022). CONCLUSIONS: Sarcopenia was associated with increased postoperative AKI incidence and overall mortality among individuals who underwent infrarenal AAA operation.